Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
142.00
-7.50 (-5.02%)
Mar 4, 2026, 12:50 PM CST
51.39%
Market Cap 231.72B
Revenue (ttm) 34.99M
Net Income (ttm) -488.25M
Shares Out 1.55B
EPS (ttm) -0.32
PE Ratio n/a
Forward PE 62.55
Dividend n/a
Ex-Dividend Date n/a
Volume 5,577,348
Average Volume 7,281,932
Open 147.00
Previous Close 149.50
Day's Range 141.50 - 147.50
52-Week Range 54.10 - 277.00
Beta 0.55
RSI 41.09
Earnings Date Feb 6, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.

Financial Statements

News

There is no news available yet.